265 related articles for article (PubMed ID: 29556048)
1. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.
Benzon B; Glavaris SA; Simons BW; Hughes RM; Ghabili K; Mullane P; Miller R; Nugent K; Shinder B; Tosoian J; Fuchs EJ; Tran PT; Hurley PJ; Vuica-Ross M; Schaeffer EM; Drake CG; Ross AE
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):126-136. PubMed ID: 29556048
[TBL] [Abstract][Full Text] [Related]
2. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Waitz R; Solomon SB; Petre EN; Trumble AE; Fassò M; Norton L; Allison JP
Cancer Res; 2012 Jan; 72(2):430-9. PubMed ID: 22108823
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model.
Li F; Guo Z; Yu H; Zhang X; Si T; Liu C; Yang X; Qi L
Neoplasma; 2014; 61(6):659-71. PubMed ID: 25341995
[TBL] [Abstract][Full Text] [Related]
4. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
5. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.
Shen YC; Ghasemzadeh A; Kochel CM; Nirschl TR; Francica BJ; Lopez-Bujanda ZA; Carrera Haro MA; Tam A; Anders RA; Selby MJ; Korman AJ; Drake CG
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):113-125. PubMed ID: 29203894
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
8. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
Muralidhar A; Gamat-Huber M; Vakkalanka S; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772685
[TBL] [Abstract][Full Text] [Related]
9. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous tumor ablation: microencapsulated echo-guided interstitial chemotherapy combined with cryosurgery increases necrosis in prostate cancer.
Le Pivert PJ; Morrison DR; Haddad RS; Renard M; Aller A; Titus K; Doulat J
Technol Cancer Res Treat; 2009 Jun; 8(3):207-16. PubMed ID: 19445538
[TBL] [Abstract][Full Text] [Related]
12. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
14. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
16. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
Wada S; Jackson CM; Yoshimura K; Yen HR; Getnet D; Harris TJ; Goldberg MV; Bruno TC; Grosso JF; Durham N; Netto GJ; Pardoll DM; Drake CG
J Transl Med; 2013 Apr; 11():89. PubMed ID: 23557194
[TBL] [Abstract][Full Text] [Related]
17. T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.
Cerqueira MA; Ferrari KL; de Mattos AC; Monti CR; Reis LO
World J Urol; 2020 Mar; 38(3):673-680. PubMed ID: 31263944
[TBL] [Abstract][Full Text] [Related]
18. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
19. Combining local cryoablation with PD-L1 blockade synergistically eradicates established murine lung cancer by modulating mitochondrial in PD-1+CD8+ T cell.
Zhai JW; Lv LL; Wu JJ; Zhang YX; Shen Y; Qu QX; Chen C
Immunol Lett; 2023 Nov; 263():61-69. PubMed ID: 37805094
[TBL] [Abstract][Full Text] [Related]
20. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
